Literature DB >> 562433

Dopamine receptor blocking activity of sulpiride in the central nervous system.

F Honda, Y Satoh, K Shimomura, H Satoh, H Noguchi, S Uchida, R Kato.   

Abstract

Effects of sulpiride on the central nervous system were studied in catalepsy induction (I) and antagonism to gnawing behaviour (II) induced by apomorphine and methamphetamine in normal rats, and in antagonism to rotational behaviour (III) induced by apomorphine and methamphetamine in rats with substantia nigra unilaterally lesioned chronically by microinjection of 6-hydroxydopamine. Sulpiride was administered orally and intraventricularly, and the effects of sulpiride were compared to those of haloperidol and chlorpromazine administered through the same routes. In oral administration, sulpiride was almost inactive in (I), and was several hundreds to a thousand times less potent than haloperidol in (II) and (III), while chlorpromazine was 20 to 150 times stronger than sulpiride. In intraventricular administration, sulpiride was almost equipotent to haloperidol in (I), and was equally effective to or 2 to 3 times more effective than halopridol in (III), although several times less in all respects. These findings suggest that sulpiride is essentially a potent inhibitory substance on dopamine receptors in the central nervous system and the rather weak central effects of peripherally given sulpiride are due to poor penetration through the blood brain barrier.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 562433     DOI: 10.1254/jjp.27.397

Source DB:  PubMed          Journal:  Jpn J Pharmacol        ISSN: 0021-5198


  15 in total

1.  Pharmacological characterization of the receptors involved in the apomorphine-induced polyphasic modifications of locomotor activity in mice.

Authors:  P Protais; J J Bonnet; J Costentin
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

2.  Atypical antidopaminergic properties of CI-686: a potential antipsychotic agent.

Authors:  M Stanley; J Rotrosen; N Sculerati; S Gershon; C Kuhn; B M Cohen
Journal:  Psychopharmacology (Berl)       Date:  1979       Impact factor: 4.530

3.  Effect of the (+)-and (-)-enantiomers of sulpiride on ADTN-induced hyperactivity in the rat [proceedings].

Authors:  C D Andrews; G N Woodruff
Journal:  Br J Pharmacol       Date:  1978-11       Impact factor: 8.739

4.  Antistereotypic effects of dopamine D-1 and D-2 antagonists after intrastriatal injection in rats. Pharmacological and regional specificity.

Authors:  J Arnt
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-08       Impact factor: 3.000

5.  Dopamine receptors in canine caudate nucleus.

Authors:  H Maeno
Journal:  Mol Cell Biochem       Date:  1982-03-19       Impact factor: 3.396

6.  Impact of D2 receptor internalization on binding affinity of neuroimaging radiotracers.

Authors:  Ningning Guo; Wen Guo; Michaela Kralikova; Man Jiang; Ira Schieren; Raj Narendran; Mark Slifstein; Anissa Abi-Dargham; Marc Laruelle; Jonathan A Javitch; Stephen Rayport
Journal:  Neuropsychopharmacology       Date:  2009-12-02       Impact factor: 7.853

7.  Autoradiographic study of 14C-sulpiride in monkey.

Authors:  A Benakis; J P Brown; P Benard
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1984 Oct-Dec       Impact factor: 2.441

8.  The actions of antipsychotic drugs on dopamine receptors in the rat substantia nigra.

Authors:  R D Pinnock
Journal:  Br J Pharmacol       Date:  1984-04       Impact factor: 8.739

9.  Differential effects of sulpiride and metoclopramide on brain. Homovanillic acid levels and shuttle box avoidance after systemic and intracerebral administration.

Authors:  Y Nishibe; Y Matsuo; T Yoshizaki; M Eigyo; T Shiomi; K Hirose
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1982-12       Impact factor: 3.000

10.  The nucleus accumbens and antidepressants: modulation of ergometrine-induced hyperactivity by typical and atypical antidepressants and neuroleptics in rats.

Authors:  A R Cools
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.